Evaluation of a Novel Antiplatelet Agent for Secondary Prevention in Patients With Atherosclerotic Disease: Results of the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events TRA 2P–TIMI 50 Trial